Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-α on macrophages through the autocrine action of IL-6

Biochemical and Biophysical Research Communications

Volumn 420, Issue 1, 2012, Pages 114-118

  Ogawa, Hiromi ^a   Mukai, Kaori ^a,b   Kawano, Yohei ^a   Minegishi, Yoshiyuki ^a   Karasuyama, Hajime ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 33; IL 4; IL 6; Inflammation; Macrophage; TNF

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOCRINE EFFECT; CELL INTERACTION; CYTOKINE PRODUCTION; DRUG POTENTIATION; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH2 CELL; WILD TYPE;

ANIMALS; AUTOCRINE COMMUNICATION; CELL MEMBRANE; INTERLEUKIN-4; INTERLEUKIN-6; INTERLEUKINS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859102118     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.124     Document Type: Article

References (31)

1. Beutler B., Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 1989, 7:625-655.
2. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992, 10:411-452.
3. Pfeffer K., Matsuyama T., Kündig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Krönke M., Mak T.W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467.
4. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., Mak T.W., Bloom B.R. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
5. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2002, 2:364-371.
6. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., van Deventer S.J. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004, 350:876-885.
7. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
8. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., Chen W.J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.L., Becherer J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
9. Vandenabeele P., Declercq W., Beyaert R., Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995, 5:392-399.
10. Kriegler M., Perez C., DeFay K., Albert I., Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988, 53:45-53.
11. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63:251-258.
12. Ruuls S.R., Hoek R.M., Ngo V.N., McNeil T., Lucian L.A., Janatpour M.J., Körner H., Scheerens H., Hessel E.M., Cyster J.G., McEvoy L.M., Sedgwick J.D. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001, 15:533-543.
13. Mueller C., Corazza N., Trachsel-Løseth S., Eugster H.P., Bühler-Jungo M., Brunner T., Imboden M.A. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J. Biol. Chem. 1999, 274:38112-38118.
14. Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004, 15:353-366.
15. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
16. Horiuchi T., Mitoma H., Harashima S., Tsukamoto H., Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010, 49:1215-1228.
17. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
18. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
19. Kreider T., Anthony R.M., Urban J.F., Gause W.C. Alternatively activated macrophages in helminth infections. Curr. Opin. Immunol. 2007, 19:448-453.
20. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
21. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., Pitman N., Mirchandani A., Rana B., van Rooijen N., Shepherd M., McSharry C., McInnes I.B., Xu D., Liew F.Y. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009, 183:6469-6477.
22. Oboki K., Ohno T., Kajiwara N., Saito H., Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 2010, 59:143-160.
23. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
24. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
25. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
26. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat. Rev. Immunol. 2010, 10:225-235.
27. Galli S.J., Grimbaldeston M., Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 2008, 8:478-486.
28. Karasuyama H., Mukai K., Obata K., Tsujimura Y., Wada T. Nonredundant roles of basophils in immunity. Annu. Rev. Immunol. 2011, 29:45-69.
29. Adrain C., Zettl M., Christova Y., Taylor N., Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012, 335:225-228.
30. McIlwain D.R., Lang P.A., Maretzky T., Hamada K., Ohishi K., Maney S.K., Berger T., Murthy A., Duncan G., Xu H.C., Lang K.S., Häussinger D., Wakeham A., Itie-Youten A., Khokha R., Ohashi P.S., Blobel C.P., Mak T.W. IRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 2012, 335:229-232.
31. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., McKenzie A.N., Kanellopoulos J. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J. Immunol. 2009, 183:1446-1455.